genocea
announces
fda
acceptance
ind
application
cambridge
globe
newswire
genocea
biosciences
nasdaq
gnca
biopharmaceutical
company
developing
neoantigen
immunotherapies
today
announced
food
drug
administration
fda
accepted
company
investigational
new
drug
ind
application
adoptive
cell
therapy
targeting
neoantigens
designed
improve
upon
limitations
til
tcr
therapies
ind
allows
genocea
initiate
phase
clinical
study
patients
failed
checkpoint
inhibitor
therapy
trial
evaluate
safety
cell
proliferation
persistence
well
clinical
activity
builds
power
platform
demonstrated
clinical
trial
identify
relevant
neoantigens
drive
robust
cell
responses
patients
regardless
hla
type
said
chip
clark
president
chief
executive
officer
genocea
using
patient
peripheral
cells
already
programmed
kill
cancer
cells
relevant
neoantigens
enables
therapy
rapidly
scale
therefore
believe
may
eventually
offer
efficacy
accessibility
cost
advantages
patients
genocea
plans
enroll
patients
across
several
tumor
types
phase
trial
one
cohort
patients
receive
multiple
low
doses
without
lymphodepletion
cohort
patients
receive
single
dose
lymphodepletion
high
dose
genocea
biosciences
genocea
mission
conquer
cancer
developing
personalized
cancer
immunotherapies
multiple
tumor
types
unique
platform
comprehensively
profiles
patient
cell
responses
potential
targets
antigens
tumor
atlas
enables
us
optimize
neoantigens
inclusion
immunotherapies
exclude
inhibitory
antigens
exert
immunosuppressive
effect
advancing
two
programs
neoantigen
vaccine
conducting
phase
clinical
trial
cell
therapy
using
cells
derived
peripheral
blood
commencing
phase
clinical
trial
learn
please
visit
statements
press
release
includes
statements
including
statements
relating
within
meaning
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
implied
statements
genocea
cautions
statements
subject
numerous
assumptions
risks
uncertainties
change
time
applicable
risks
uncertainties
include
identified
heading
risk
factors
included
genocea
annual
report
form
year
ended
december
subsequent
sec
filings
statements
speak
date
press
release
genocea
assumes
duty
update
statements
except
may
required
law
investor
contact
dan
ferry
daniel
